Procalcitonin Guided Antibiotic Stewardship

Girum Tesfaye Kiya[1], Elsah Tegene Asefa[2], Gemeda Abebe[1] and Zeleke Mekonnen[1]

[1]School of Medical Laboratory Sciences, Jimma University, Jimma, Ethiopia. [2]Department of Internal Medicine, Jimma University, Jimma, Ethiopia.

ABSTRACT: Despite infection and sepsis being a major public health challenge, early detection and timely management are often hindered by several factors. These includes the similarity of clinical presentations between infectious and non-infectious conditisons, as well as limitations of current diagnostic methods such as lengthy turnaround times and low sensitivity. Consequently, there is increasing interest in identifying biomarkers that can quickly and accurately differentiate bacterial sepsis from other inflammatory processes, whether infectious or non-infectious. Procalcitonin has emerged as one of the most extensively studied and utilized biomarkers in managing infection and sepsis, especially within the framework of antibiotic stewardship. This review aims to examine the role of Procalcitonin in guiding antibiotic stewardship. It explores the production and release of procalcitonin and its relevance in the context of infection and sepsis. The discussion focus on the clinical and economic impacts of using procalcitonin to guide the initiation and discontinuation of antibiotics in managing these conditions.

KEYWORDS: Procalcitonin, antibiotic stewardship, antibiotic initiation, antibiotic cessation, sepsis, infection

Introduction

The gold standard for managing infection and sepsis is pathogen identification followed by targeted antibiotic treatment. However, this approach is often impractical due to the long turnaround times (1) and low sensitivity (2) of microbial cultures.[1] Consequently, the current guidelines recommend the immediate administration of broad-spectrum antimicrobials,[2] before identifying the causative agent. This practice can lead to inappropriate antimicrobial use and increased risk of resistance development,[3] potential opportunistic infections,[4] and a significant economic burden.[5]

Given these ongoing challenges, there has been a substantial focus in research on identifying alternative biomarkers that can accurately and rapidly differentiate bacterial sepsis from other infectious and non-infectious inflammatory conditions.[6] These biomarkers can be broadly classified into pathogen-specific and host-response biomarkers. Pathogen-specific biomarkers, which are often antigens of specific pathogens, are detected using techniques such as enzyme immunoassay, fluorescence immunoassay or immunochromatographic methods, each with varying degrees of sensitivity and specificity.[7]

Host-response biomarkers are typically associated with the body's initial immune response to infection and have shown both prognostic and diagnostic value.[8] An ideal biomarker should possess the ability to accurately diagnose conditions, predict disease outcomes, and effectively guide antibiotic therapy.[9,10] Procalcitonin (PCT) is one of the most widely studied and utilized biomarker in the management of infection and sepsis.[9] Several randomized controlled trials and meta-analyses have extensively evaluated PCT in the context of antibiotic stewardship.[11-13] While the majority of these studies highlight the importance of PCT in guiding antibiotic use, a few have not found sufficient evidence to support its efficacy. This review aims to explore the opportunities and challenges associated with the use of PCT in guiding antibiotic therapy. It will mainly cover the clinical and economic impact of PCT-guided antibiotic stewardship. Additionally, a preliminary overview will be provided on PCT production, kinetics, analysis, and related interferences.

Procalcitonin

Procalcitonin is a 116 amino acid protein with a MW of 14.5 kDa and serve as a precursor to the hormone calcitonin (CT), which plays a role in calcium homeostasis.[14,15] It is encoded by the CALC-1 gene located on the short arm of chromosome 11. Pre-procalcitonin (pre-PCT) undergoes a series of proteolytic cleavage to form PCT, which subsequently processed into calcitonin. The expression of CALC-1 gene is typically restricted to neuroendocrine cells, primarily the C cells of the thyroid gland.[16] In healthy individuals, PCT production is tissue-specific and undergoes post-translational processing to produce small peptides and mature CT.[14] Elevated calcium levels and other stimuli, such as glucocorticoids, glucagon, gastrin or β-adrenergic stimulation activate thyroid C-cells to produce CT, whereas, somatostatin and vitamin D inhibit its production.[17]

Almost all of the PCT produced in the thyroid C-cells is converted to CT, resulting in PCT levels in healthy individuals being below the detectable limits (18). If PCT does enter the circulation, it has a half-life of 25 to 30 hours, after which it is cleared, as there is no enzyme specifically responsible for breaking down the circulating PCT.[17]

Under normal physiological conditions, PCT is formed in the thyroid C-cells and converted to CT, which helps regulate calcium homeostasis. However, during microbial infection and inflammation, non-neuroendocrine tissues including, adipocytes, liver, kidney, and lungs, also contribute to PCT synthesis.[18] In inflammatory states, not only does the thyroid produce

Figure 1. Procalcitonin Production During Inflammation. The figure shows increased procalcitonin (PCT) synthesis in response to bacterial infections due to cytokines (IL-1β, IL-6, TNF-α) and lipopolysaccharide (LPS). Viral infections trigger interferon gamma (IFN-γ), which suppresses PCT production. CT-mRNA: Calcitonin messenger RNA; LPS: lipopolysaccharide; IFN- γ: Interferon gamma; IL-1β: Interleukin 1 beta; IL-6: Interleukin 6; TNF- α: Tumor necrosis factor alpha.

PCT at levels exceeding the capacity of converting enzymes, but additional production from various tissues can increase PCT concentration by 100 to 1000-fold.

During bacterial infection, PCT production increases in response to the release of microbial components like lipopolysaccharides or other toxic metabolites, as well inflammatory cytokines such as interleukin 1β (IL-1β), IL-6 and tumor necrosis factor alpha (TNF-α).[19] This phenomenon was demonstrated in primates injected with lipopolysaccharide, where PCT mRNA was expressed in various cell types, resulting in elevated PCT levels since most cells could not convert PCT to calcitonin.[20] Elevated PCT concentration during severe bacterial infection in patients who had undergone total thyroidectomy further suggested that PCT is secreted by various extrathyroidal tissues throughout the body.[21] Conversely,, cytokines produced during viral infections, such as interferon gamma (IFN-γ), suppresses CALC-1 gene expression, leading to low PCT production.[9] This characteristic makes PCT

particularly useful for differentiating between viral and bacterial infections (Figure 1).

Procalcitonin kinetics

Procalcitonin (PCT) exhibits a kinetic profile that is highly useful for monitoring patients' status and guiding antibiotic therapy. PCT levels become detectable within 2 to 4 hours of infection, rising typically within 6 to 12 hours and peaking around 24 hours.[22] This rapid increase allows clinicians to assess the severity of the infection. Conversely, PCT level quickly decline when the infection is controlled.[14,15] PCT levels correlate with interleukin -6 (IL-6) and tumor necrosis factor alpha (TNF-α), which are key cytokines involved in the inflammatory response to infection.[23] A significant decrease in PCT levels overtime suggests a positive response to therapy, providing valuable insights into the effectiveness of the chosen antibiotic regimen. The trajectory of PCT plasma concentration has

become an important focus in the diagnosis and monitoring of infectious diseases.

Due to the sustained expression of PCT during infection and its decline during recovery, monitoring PCT kinetics over time offers significant prognostic value.[15] Several studies demonstrated that PCT non-clearance over time was a good predictor of 28/30-day mortality,[24-27] whereby PCT clearance was defined as a decrease in PCT level by 25% or more in 48 hours to 7 days.

It should be noted that other inflammatory processes can cause transient increase in PCT levels though this increases are generally lower compared to those seen in bacterial infection (28). The rapid rise in PCT levels, peaking 6 hours after endotoxin injection and remaining elevated for 25-30 hours, makes PCT a promising biomarker to differentiating bacterial infection from non-bacterial ones, often even before microbiological culture results are available.[28]

Different cut-off values for PCT are used depending on the clinical condition and the purpose of the measurement. Schuetz et al.[29] reviewed the evidence for PCT cut-offs across various infections and clinical settings. For patients with low acuity, such as those typically presenting to the emergency department (ED) without sign of severe infection or sepsis, a single PCT measurement with a cut-off between less than 0.10 to less than 0.25 ng/ml is likely indicative of non-bacterial infections, such as bronchitis or viral-induced exacerbation of Chronic Obstructive Pulmonary Disease (COPD). For patients transferred to ICU due to severe illness, initial empiric antibiotic therapy is recommended for all suspected sepsis cases. In such settings, the PCT algorithm primarily guides discontinuation of antibiotics during follow-up, with daily PCT measurements. Antibiotic discontinuation is advised when PCT levels decreases by >80% from the peak value or fall below an absolute value of 0.5 ng/ml, while closely monitoring the patient's clinical status. Treatment failure is indicated if PCT levels remain elevated.

These cut-off values may not be applicable to individuals with kidney disease, as renal function significantly influences plasma PCT levels. Several studies suggest using higher thresholds for patients with impaired kidney function.[30-33] While the exact elimination route of PCT is not fully understood, its low molecular weight of 14 kDa, suggests that renal function could affect PCT levels.[31] Additionally, renal impairment might indirectly elevate PCT levels by increasing serum concentrations of proinflammatory metabolites, which activate the immune system, leading to heightened inflammation and increased PCT release into circulation.[34] For instance, Wu et al. reported a higher PCT levels in chronic kidney disease (CKD) patients (0.44 ± 0.67 ng/mL) compared to healthy controls (0.04 ± 0.06 ng/mL), with patients in stage 5 CKD showing a significantly elevated PCT level (0.50 ± 0.73 ng/mL).[30] Similarly, El-sayed et al. suggested that a single threshold is unreliable for predicting bacterial infection in patients

with renal impairment, proposing a threshold of 3.2 ng/mL above which bacterial infection is highly likely, and below 0.5 ng/mL, infection is unlikely.[33] However, Meisner et al, observed only a moderate and clinically insignificant prolongation of PCT clearance in patients with severely impaired renal function compared to those with normal renal function.[35,36] This suggests that renal secretion plays a minor role in PCT elimination, and the slightly increased clearance time might be due to persistent inflammation in patients with severe renal impairment.

Host factors

The impact of host immune status on PCT levels has received significant research attention. Earlier studies suggested that PCT's utility in severely leukopenic patients (WBC $< 1 \times 10^9$/L) was inadequate,[37] promoting a need for new PCT cut-offs for immunocompromised patients.[38] This was based on concerns that leukocytes might be a primary source of PCT production during infection. However, recent findings do not support reduced PCT levels in immunosuppressed individuals. Unlike markers like white blood cells (WBCs), PCT levels are generally not affected by immunocompromising conditions or leukopenia-inducing medications, as PCT is secreted not only by leukocytes but also by various tissues throughout the body.[39] PCT response is not suppressed by immunosuppressive medications; in fact increased concentration have been reported in immunosuppressed patients with confirmed infection compared to non-immunosuppressed patients with infections.[40] A meta-analysis by Wu et al. showed that PCT has higher diagnostic value than other biomarkers, such as CRP and IL-6, for detecting bacterial infection in patients with febrile neutropenia.[41] Similar to other populations, PCT levels are effective in ruling out bacterial infection in immunosuppressed patients[42] and solid organ transplant recipients.[43]

Using PCT level as a marker of bacterial infection in the first days of life presents several challenges. For instance, infants with conditions such as respiratory distress syndrome, hemodynamic failure, perinatal asphyxia, intracranial hemorrhage, pneumothorax, or those undergoing resuscitation can exhibit elevated serum PCT levels similar to those seen in septic neonates within the first 48 hours of clinical signs of distress or infection.[44] Additionally, in healthy neonates, PCT levels typically rise before term or at term and peak within 18-30 hours after birth, returning to normal levels by 42-48 hours.[45] Gestational age (GA) significantly affects PCT levels, with preterm neonates showing higher and more prolonged elevations compared to term neonates. This variation necessitates the use of reference PCT values tailored to GA and days of life for diagnosing early onset sepsis (EOS).[46] Altunhan et al, reported an increased PCT level at 24 hours of life compared to levels at birth, proposing a cut-off values of 0.59 ng/ml at birth and 5.38 ng/ml at 24 hours.[47] However, notable differences

exist between healthy and septic neonate: septic neonates exhibit much higher increase in PCT levels, and failure to decrease after an initial rise suggests persistent bacterial infection.[48] For late-onset sepsis (LOS), physiological variation do not interfere, making PCT level a reliable indicator of the neonate's condition.[49] The Adult reference ranges can be applied to newborns after three days of birth.[50]

Procalcitonin analysis

Procalcitonin can be reliably analyzed using serum or plasma samples collected in EDTA or heparin anticoagulants.[51] Whole blood samples also provide consistent results, making them suitable for procalcitonin measurement.[52,53] For accurate PCT analysis, serum or plasma samples should be separated and analyzed within 4 hours of blood collection. They can be stored at 2-8°C for upto 24 hours; for longer, storage, samples should be refrigerated at −20°C within 48 hours. A single freeze-thaw cycle may reduce PCT recovery of up to 8%. Prior to analysis, all samples should be centrifuged to remove fibrin or other particulate matter.[54]

Numerous commercially available platforms for PCT assays differ in technical characteristics such as sensitivity, processing time, and detection limit.[55] The original manual PCT assay, the B·R·A·H·M·S PCT LIA (formerly the LUMItest PCT), was a one-step immunoluminescence assay with limited sensitivity, capable of detecting only markedly elevated PCT levels with a functional assay sensitivity of 0.3 ng/ml and lower detection limit (0.1 ng/ml).[56] This assay has been replaced by more sensitive automated immunoassay methods, such as the B·R·A·H·M·S PCT sensitive Kryptor® assay. Although there is no reference method for PCT detection, the B·R·A·H·M·S PCT sensitive Kryptor® assay is often considered as a gold standard, as it was among the earliest methods used in clinical trials that established PCT cut-offs for antibiotic stewardship decisions.[15]

The assay uses polyclonal antibodies against calcitonin (CP) and monoclonal antibodies against katacalcin (CCP-I) domains of PCT. When PCT is present in the sample, it forms an immunocomplex by being sandwiched between these antibodies.[57] This method is highly sensitive, with lower detection limit of 0.02 ng/ml and a functional assay sensitivity of 0.06 ng/ml.[55] B·R·A·H·M·S licensed reagents containing the B·R·A·H·M·S PCT antibody have been incorporated into various automated platforms, including ADVIA Centaur (Siemens Healthcare), ARCHITECT (Abbott), Cobas ELECSYS (Roche Diagnostics), VIDAS (Biomerieux), and LIAISON (DiaSorin), among others.

The Diazyme PCT assay utilizes a latex-enhanced immunoturbidimetric method in which PCT binds to specific anti-PCT antibodies coated on latex particles, resulting in agglutination. The resulting turbidity is measured at 600 nm, and its intensity is directly proportional to the concentration of PCT in the sample. The final PCT concentration is calculated by interpolating the optical signal against a 6-point calibration curve.[58] The Diazyme PCT reagent system is also compatible with several automated instruments, including ADVIA 2400, ARCHITECT c16000, Roche cobas c 501, and Roche cobas c 702, among others. A detailed comparison of PCT assays, including performance evaluations against the B•R•A•H•M•S PCT sensitive Kryptor® and comparability across different platforms, is available in other sources.[15]

Interfering factors

Several clinical conditions and factors can influence PCT results. Falsely elevated PCT results may occur in situations like severe trauma or burns, major surgery, cardiogenic shock, and treatments including cytokine-stimulating agents.[59] PCT levels typically rise rapidly, peaking at 24 hours post-trauma, and decline quickly in non-complicated patients cases.[59] A persistent rise,[60] a biphasic increase after 1 week,[61] or a significantly higher rise compared to non-infectious systemic inflammatory response syndrome (SIRS)[60] is associated with development of sepsis. Therefore, repeated measurements rather than a single value, are recommended for optimal clinical decision-making.

PCT levels elevate within 24 hours in patients with burn injuries, independent of infection, due to the immediate inflammatory response, and typically return back to normal by the third day. However, in the presence of sepsis, PCT value continues to rise rapidly, reaching values greater than 5-100 ng/mL.[62,63] A similar PCT kinetic pattern is observed in patients undergoing abdominal surgery.[64,65] While there is a slight increase in PCT levels 1 day post-operation, these levels continue to rise in patients with postoperative infectious complications.

False negative PCT results may occur in localized infections such as osteomyelitis, abscess, subacute endocarditis; or when PCT is measured too early in disease course.[22] This highlights that a low or normal PCT does not always preclude the presence of bacterial infections.

Antibiotic guidance using PCT

Procalcitonin is one of the most extensively studied biomarkers in the context of antibiotic stewardship for patients with infections. Numerous randomized controlled trials and meta-analyses have assessed the effectiveness of PCT in guiding the initiation and de-escalation of antibiotics using specific cut-off points. These studies typically compared PCT-guided antibiotic initiation and discontinuation with the standard of care (SOC) practices, which rely on the physician discretion or established national and international guidelines. The clinical and economic impacts of using PCT to guide antibiotic initiation and cessation are discussed in the following sections.

Procalcitonin guided initiation of antibiotics

Procalcitonin is well studied for its utility in helping clinicians decide when to start antibiotics and determine the appropriate

duration of treatment. One of the key challenges in clinical practices is accurately distinguishing between the need for prompt antibiotic initiation and avoiding unnecessary antibiotic use when infection is not present. A reliable biomarker that guides these decisions is therefore of high importance. While most clinical studies have concentrated on evaluating the role of PCT-guided strategies for discontinuing antibiotics, some studies, as discussed in the proceeding paragraphs, have explored the effectiveness of using PCT for guiding the initiation antibiotic therapy.

In a randomized controlled trial conducted across 5 ICUs with 509 adult participants, patients were randomized to receive either a PCT-guided approach or SOC approach for antibiotic management. In the PCT group, antibiotics were not initiated for patients with PCT levels < 0.25 ng/ml, while antibiotics were started for those with PCT levels > 1 ng/ml.[66] In the control group, physicians were blinded to PCT results. This study found no significant difference between the PCT and control groups regarding the initiation of antibiotics. Notably, 46% of patients with suspected sepsis in the PCT group were not eligible for antibiotic treatment due to PCT level below <0.25 ng/ml, compared to 32.7% in the control group. However, antibiotics were still administered to 43 patients in the PCT group with PCT level <0.25 ng/ml, most of whom had lower respiratory tract infection. As a result, the overall antibiotic consumption between the two groups was not significantly different as assumed. This outcome could be attributed to nearly half of the participants in the PCT arm having PCT levels >1 ng/ml, making them eligible for antibiotics. The study concluded that relying solely on PCT levels for antibiotic initiation was not particularly helpful. However, there was notable significant reduction in antibiotic consumption when clinicians considered the patient's PCT levels alongside the clinical context of possible infection.

The Procalcitonin and Survival Study (PASS), a randomized controlled trial conducted in nine university hospitals in Denmark from 2006 to 2009, involved 1200 critically ill adult patients. Its objective was to assess whether procalcitonin-guided antimicrobial escalation reduces the time to appropriate therapy.[67] In the SOC group, antimicrobial treatment was guided based on the existing guidelines while in the PCT group antimicrobial intervention was further guided by the daily PCT measurement classified as "alert PCT" (>1.0 ng/mL and not decreasing by at least 10% from the previous day) and "non-alert PCT" (SOC only guided diagnostics and antimicrobial therapy plus de-escalation of antimicrobial therapy when PCT <1.0 ng/mL for at least 3 days). In this study, broad spectrum antimicrobial therapy consumption was higher in the PCT group as compared to the SOC and the median length of antibiotic course in the ICU was 2 days longer [PCT median 6 days (interquartile range [IQR] 3–11] vs SOC of 4 days (IQR 3-10). While the 28-day mortality was comparable between the two groups, time spent on mechanical ventilation

and length of stay in the ICU is longer among PCT group as compared to the SOC group. Therefore, the authors concluded that escalation of broad-spectrum antimicrobials using PCT level guidance led to increased consumption of antimicrobials, raising concern on resistance and toxicity, and did not reduced mortality. Moreover, the study reported the significant increase in cost of using PCT guided approach. This is mainly due to the repeated analysis of PCT itself, use of additional broad-spectrum antibiotics, additional requirement of culture, more days on mechanical ventilation, and longer stay in the ICU.

Similar results were reported in different meta-analyses that determined the role of PCT in antibiotic guidance. A meta-analysis by Peng et al., that included 16 RCTs and enrolled 6452 critically ill patients, showed that PCT-guided initiation of antibiotic therapy reduced neither the short-term mortality nor the length of stay of critically ill sepsis patients.[68] Similarly, the efficacy of PCT-guided initiation of antibiotic therapy could not be verified by a meta-analysis by Huang et al.[69] A meta-analysis by Prkno et al. that focused on both escalation and discontinuation of antibiotics based on PCT level, showed that there was no significant difference between PCT-guided approach and SOC approach with respect to 28-day mortality, and length of stay in the ICU and in-hospital stay.[70]

Procalcitonin guided cessation of antibiotics

Antimicrobial resistance is a rapidly growing public health concern particularly in the ICUs due to the weight of broad-spectrum antimicrobial use. One of the risk factors is prolonged duration of antimicrobial treatment.[71] PCT is a biomarker that has been well studied for its utility to discontinue antimicrobial therapy and hence yielded a shorter duration of therapy as compared to the SOC. Several RCTs showed the importance of PCT to discontinue antibiotic treatment at a given cut off (usually PCT<0.5 ng/ml) or a relative decrease in PCT by a given percentage (usually 80% or more) from peak value.

Antibiotic cessation in sepsis patients

We reviewed 15 clinical studies that recruited sepsis, severe sepsis, or septic shock patients,[72,73-85] of which two studies[75,81] involved neonates born after 34 weeks of GA suspected to have EOS (Table 1). Overall, the studies involved 3143 patients in the PCT group and 3144 in the control group, and half of them were multicenter studies. There was variability in the frequency of PCT measurement whereby some of them measured PCT daily starting from day of enrollment,[77,78,82,84] while others measured every other day[74,80,86] or every 2 or 3 days.[72,73,76,79,81] Moreover, absolute cut-offs of PCT to discontinue antibiotic therapy varied across studies. The thresholds were 0.25 ng/ml,[78,85] 0.5 ng/ml,[72-74,77,79,80,83] or 1.0 ng/ml.[76,83,84] The cut-off points used for studies that involved neonates were multiple depending on the hour of measurement after birth (Supplemental Figure 1).[75] Alternative to the cut-off points,

Table 1. Characteristics of 15 clinical studies involving Sepsis patients.

AUTHOR, YEAR, COUNTRY [REF]	SETTING	ASSAY USED	FREQUENCY OF PCT MEASUREMENT	PCT ALGORITHM	SAMPLE SIZE	OUTCOMES: PCT VS SOC
Ali, 2021, Egypt[72]	Sepsis or septic shock adults in medical ICU, Single center	ELISA (PCT, Sigma-Aldrich, USA)	Day 1, 4, and 7	Discontinue: PCT <0.5 ng/ml or PCT decrease by ≥80%-90% from baseline	PCT=30 CRP=30	Patients on AB after 7 days: 33% vs 83%, p=.001 28-day mortality: 34.8% vs 65.2%, p=.063
Kyriazopoulou, 2021, Greece[73]	adults admitted to internal medicine departments who met sepsis-3 definition, multicenter	VIDAS assay (bioM'erieux)	Day 1 and 5	Discontinue: PCT <0.5 ng/L at Day 5 or later or ≥80% reduction from baseline	PCT=125 SOC=131	Infection associated adverse events: 7.2% vs 15.3% AB duration: 5days vs 10days, P<.001 28-day mortality:15.2% vs 28.2% (hazard ratio, 0.51; 95% CI, 0.29–0.89; P=.02)
Jeon, 2019, Korea[74]	Severe sepsis or septic shock adults in medical ICU, single center	Not reported	Every other day from day 1 to day 14 or until antibiotics were stopped	Discontinue: PCT<0.5ng/mL or ≥80% reduction from baseline	PCT=23 SOC=29	AB duration: 10 vs. 13days, p=.078 28-day mortality: 17% vs 21%, p=.709
Stocker, 2017, Canada, Europe (Dutch, Swiss, Czech)[75]	Neonates born after 34weeks of GA and suspected of EOS, multicenter	Roche Elecsys BRAHMS	At inclusion and 12h after inclusion	Discontinue: After 24 h, if 2 consecutive procalcitonin values within range (the range depends on h after birth	PCT=866 SOC=844	AB duration: 55·1 h vs 65·0h, P=.0001
Bloos, 2016, Germany[76]	Severe sepsis or septic shock adults in ICUs, multicenter	Not explicitly mentioned – described as time-resolved amplified cryptate emission technology	Days 0, 1, 4, 7, 10 and 14 if patient still in ICU.	Discontinue: on days 7, 10 or 14: if PCT <1ng/mL or PCT>1ng/m ≥ and PCT decrease ≥50% from previous value	PCT=552 SOC=537	AB duration: per 1000 ICU days: 823 vs 862 days, decrease by 4.5%, p=.02 28-day mortality: 25.6% vs 28.2%, p=.34
De Jong, 2016, France[77]	Sepsis, severe sepsis, septic shock adults in ICU, multicenter	Kryptor, Vidas, or roche depending on site	Daily until ICU discharge or until 3days after systemic antibiotics stopped.	Discontinue: PCT < 0.5ng/mL or ≥ 80% drop from baseline	PCT=761 SOC=785	AB duration: 5 vs 7days, p<.0001 28-day mortality: 19.6% vs 25%, p=.0122 Mortality (1 year): 34.8% vs. 40.9%, p=.0158
Shehabi, 2014, Australia[78]	Sepsis, severe sepsis, or septic shock adults in ICU, multicenter	Not explicitly mentioned – "automated immunoassay analyzers"	Daily until the first of ICU discharge or 7days.	Discontinue: PCT < 0.1 ng/mL, or PCT= 0.1-0.25ng/mL and infection is unlikely, or ≥ 90% drop from baseline	PCT=196 SOC=198	AB duration: 9 vs 11days, p-0.58 90-day mortality: 18% vs. 16%, p=.6

(Continued)

Table 1. (Continued)

AUTHOR, YEAR, COUNTRY [REF]	SETTING	ASSAY USED	FREQUENCY OF PCT MEASUREMENT	PCT ALGORITHM	SAMPLE SIZE	OUTCOMES: PCT VS SOC
Deliberato, 2013, Brazil[79]	Sepsis, severe sepsis, or septic shock adults in ICU, single center	VIDAS BRAHMS (bioMérieux)	Day 0, 5 or 7 (if blood culture is positive), every 48 h until hospital discharge, death, or antibiotics stopped.	Discontinue: PCT <0.5 ng/mL or ≥ 90% drop from peak value	PCT=42 SOC=39	AB duration: 10 vs 11 days, $p = .44$ In-hospital mortality: 4.8% vs 10.3%, $p = .42$
Annane, 2013, France[11]	Sepsis adults in ICU, multicenter	BRAHMS PCT-sensitive Kryptor assay	Within 6 h, day 3 and day 5 post-randomization	Discontinue: PCT <0.5 ng/mL	PCT=30 SOC=28	AB duration: 5 vs 5 days, $p = .52$ In-hospital mortality: 23 vs. 33%, $p = .4$
Oliveira, 2013, Brazil[80]	Severe sepsis or septic shock adults, 2 centers	Vidas BRAHMS PCT (bioMérieux, Lyon, France)	Day 1, and 4	Discontinue: PCT <0.1 ng/mL, or ≥ 90% drop of the highest value previously observed	PCT=49 CRP=45	AB duration: 7 vs 6 days, $p = .06$ 28-day mortality: 32.7 vs. 33.3%, $p = 1.000$
Stocker, 2010, Switzerland[81]	Neonates born after 34 weeks of GA and suspected of EOS in the first 3 days, single center	Kryptor PCT, BRAHMS, Henningsdorf, Germany	At the beginning of therapy, after 12 h, 24 h, 48 h, 96 h	Discontinue: two consecutive PCT values were below the predefined age-adjusted cut-off values	PCT=60 SOC=61	AB duration: 79.1 vs 101.5 h, $p = .012$
Bouadma, 2010, France[82]	Adults suspected with bacterial infection and admitted to ICU, multicenter	Kryptor procalcitonin, Brahms, Hennigsdorf, Germany	Day 0, then daily until treatment was completed.	Discontinue: PCT <0.5 ng/mL or ≥ 80% drop from peak value	PCT=307 SOC=314	AB duration: 10.3 vs 13.3 days, $p < .001$ 28-day mortality: 21.2 vs. 20.4%
Hochreiter, 2009, Germany[83]	Sepsis, single center	BRAHMS PCT LIA® (BRAHMS Aktiengesellschaft, Henningsdorf, Germany)	Not reported	Discontinue: PCT < 1 ng/mL or ≥ 1 ng/mL and 25-35% drop from peak value over 3 days	PCT=57 SOC=53	AB duration: 5.9 vs 7.9 days, $p < .001$
Schroeder, 2009, Germany[84]	Severe sepsis, single center	BRAHMS PCT LIA® assay in serum (B.R.A.H.M.S Aktiengesellschaft, Henningsdorf, Germany)	Daily until day 10	Discontinue: PCT < 1 ng/mL or ≥ 1 ng/mL and 25-35% drop from peak value over 3 days	PCT=14 SOC=13	AB duration: 6.6 vs 8.3 days, $P < .001$
Nobre, 2008, Switzerland[85]	Severe sepsis, septic shock, single center	Brahms Kryptor PCT	Day 0, then Day 3 if initial PCT <1 ng/mL or day 5 if initial PCT ≥1 ng/mL.	If baseline ≥1: stop when (1) PCT <0.25 ng/mL or (2) ≥ 90% drop from peak value If baseline <1: stop when PCT <0.1 ng/mL	PCT=31 SOC=37	AB duration: 6 vs 9.5 days, $p = .15$ 28-day mortality: 20.5% vs 20%, $p = .82$

AB: antibiotics; ELISA: enzyme linked immunosorbent assay; EOS: early onset sepsis; GA: gestational age; ICU: intensive care unit; PCT: procalcitonin; SOC: standard of care.

most studies used an approach to discontinue antibiotic therapy based on relative decrease of PCT from the baseline or peak value. A decrease by ≥80%-90% of the baseline or peak value was the most common approach across the studies, while a couple of studies used a decrease by ≥50%,[76] and by ≥25%-30%.[83,84]

Most studies reported reduction in duration of antibiotics in PCT groups compared to the SOC groups, the reduction ranging from 1 day to 5 days. One study[11] reported similar days of antibiotic exposure in both groups, while 3 studies[78,79,80] showed lack of statistically significant difference in antibiotic duration between the two groups. Eight studies reported 28-day mortality,[72-74,76,77,80,82,85] two studies reported in-hospital mortality,[79,80] and one study each reported 90-day and 1 year mortality.[77,78] The 28-day mortality rate in the PCT group was lower than the control group in all studies except two studies,[82,85] though the decrease was statistically significant only in three studies.[72,73,77] The reported in-hospital mortality and 90-day mortality were not statistically significantly different between the two groups, whilst the difference in 1-year mortality was statistically significant (Table 1).

Antibiotic cessation in respiratory tract infection

As presented in Table 2, we reviewed 22 clinical studies that involved patents with respiratory tract infection. Overall, 3272 patients were involved in the PCT group while 3221 patients were involved in the SOC group. Most of the studies recruited adult patients except one study[86] that recruited elderly patients aged >80 years, and two studies recruited children and adolescents.[87,88] Two-third of the studies were multicenter by design and patients with chronic obstructive pulmonary disease (COPD)[89-92] and community acquired pneumonia (CAP)[88,93-95] were the focus in four studies each. Most of the studies measured PCT every other day starting from the day of enrollment,[86-90,95-99] while few studies measured at daily basis.[91,100,101] The absolute cut-off point of PCT to discontinue antibiotic therapy was 0.25 ng/ml in all of the studies except one study that used a value of 0.5 ng/ml.[101] The other study used a PCT value of <0.5 ng/ml to initiate Azithromycin and PCT > 0.5 ng/ml to initiate levofloxacin.[102] Moreover, there were studies that used a relative decrease of PCT from peak value by >80%-90%.

Most studies reported reduction in duration of antibiotics in PCT groups compared to the SOC groups with an average reduction of 2.3 days. Three studies[90,98,104] reported almost similar days of antibiotic exposure in both groups, while six studies[90,96,98,101,104,105] showed lack of statistically significant difference in antibiotic duration between the two groups. Six studies reported 28-day or 30-day mortality,[91,94,96,97,99,102] one study reported in-hospital mortality, (104) and one study reported 90-day mortality.[90] The 28-day or 30-day mortality rate in the PCT group was lower than the control group in all studies except two studies[91,99] that reported higher mortality

rate among the PCT group, and one study[96] reported similar mortality rate. However, the decreased mortality rate in PCT groups was not statistically significant in all studies. In addition, the reported in-hospital mortality and 90-day mortality were not statistically significantly different between the two groups (Table 2).

Economic Impact

Another crucial aspect of implementing PCT-guided antibiotic stewardship is evaluating its cost-effectiveness. While cost of repeated PCT measurement in the laboratory may be considered, it should be weighed against the cost reductions achieved through shortened antibiotic use. Jensen et al. found that the cost of using PCT-guided strategy for initiating antibiotics increased significantly. This was due to repeated PCT bioanalysis, additional use of broad- spectrum antibiotics, extra culture samples, extended use of mechanical ventilation and dialysis, and a longer ICU stay.[67] Conversely, as discussed in the following paragraphs, studies have shown significant cost saving when using PCT-guided approach to discontinue antibiotic therapy as compared to standard care.

Garnfeldt et al. investigated the budget impact of PCT-guided antibiotic stewardship among ICU admitted patients suspected of sepsis in Belgium.[108] The study compared the PCT-guided approach with SOC regarding annual budget impact on the Belgian health care system. Key model parameters included the duration of antibiotic therapy, mechanical ventilation, ICU and regular ward stays, the number of PCT tests per patient, and the unit costs of these variables. The results showed that PCT-guided approach reduced antibiotic exposure days by 66,868 days per year leading to cost savings of €1.98 million. On the other hand, implementing PCT-guided antibiotic stewardship for patients suspected of sepsis costs €68,220 (€1.90 per patient). The model also projected significant cost saving for the Belgian healthcare system, estimating potential saving of up to €49.90 million. These savings were primarily attributed to reductions in ICU length of stay and the duration of mechanical ventilation use.

Acost impact analysis by Geraerds et al. comparing health care costs between SOC and PCT-guided decision making based on the NeoPInS algorithm in neonates found no significant cost difference between the two groups (€3649 in PCT-group vs. €3616 in SOC group, $P = .240$).[109] However, sub-group analysis revealed varying results. For neonates categorized under the "infection unlikely" group, the cost of PCT-guided approach was less costly, where as in the "infection possible" group, PCT-guided approach was slightly more expensive compared to SOC. Exclusion of serious adverse events and related additional days of hospitalization resulted in significantly shorter hospital stay and lower total health care costs in the PCT-guided arm as compared to the SOC arm.

A study by Garay et al. assessed the budget impact of using PCT to guide treatment in sepsis patients in Argentina.[110] This study compared costs and outcomes between SOC and

Table 2. Characteristics of 22 clinical studies involving patients with respiratory tract infection.

AUTHOR, YEAR, COUNTRY [REF]	SETTING	ASSAY USED	FREQUENCY OF PCT MEASUREMENT	PCT ALGORITHM	SAMPLE SIZE	OUTCOMES: PCT VS SOC
Gavazzi, 2022, French[86]	Old patients (> 80 years) admitted for pneumonia, multicenter	miniVidas® B.R.A.H.M.S PCT	Days 2, 4, 6, and 8 post-admission, and then after discharge or on Day 15	Discontinue: PCT < 0.25 ng/mL or ≥90% drop from peak value	PCT=50 SOC=57	AB duration: 8 vs 10 days, $p = .001$
Lhopitallier, 2021, Switzerland[105]	Adults with acute cough, multicenter	BRAHMS PCT direct POC test (Thermo-Fischer Scientific)	Not reported	Antibiotic recommended: PCT ≥0.25 ng/mL	PCT=163 SOC=114	Probability of antibiotic prescription by day 28: 0.4 vs 0.6
Mazlan, 2021, Malaysia[96]	Adults in ICU with VAP, single center	Finecare Plus analyser (Wondfo, Guangzhou, China)	Days 1, 3, 7, and 9	Discontinue: PCT < 0.25 ng/mL, or ≥ 80% drop from peak value	PCT=43 SOC=42	AB duration: 10.3 vs 11.5 days, $P = .049$ 28-day mortality: 11.6 vs 16.7%, $p = .79$
Montassier, 2019, France[95]	Adults admitted to ED with CAP, multicenter	BRAHMS Kryptor	On enrollment and days 0, 3, 5, and 7	Discontinue: PCT <0.25 ng/mL	PCT=142 SOC=143	AB duration: 9 vs 10 days, $p = .21$. 30-day mortality: 2% vs 2%
Wussler, 2019, Switzerland[103]	Adults in ED with acute dyspnea, multicenter	VIDAS BRAHMS	On enrollment and day 5.	Discontinue: PCT <0.25 ng/mL or ≥ 80% drop from PCT level at randomization	PCT=25 SOC=20	AB duration: 10.5 vs 10.5 days, $p = .387$. In-hospital mortality: 20.8% vs 20%, $p = 1.000$
Daubin, 2018, France[90]	Adults in ICU with COPD, multicenter	Elecsys BRAHMS PCT	6h after enrollment, then days 1, 3 and 5.	Discontinue: PCT <0.25 ng/mL or ≥90% drop from PCT level at randomization	PCT=151 SOC=151	AB duration: 7.9 vs 7.7 days, $p = .75$. 90-day mortality: 20% vs 14% (95% CI for adjusted difference −0.3 to 13.5%)
Huang, 2018, USA[97]	Adults in ED with LRTI, multicenter	Vidas BRAHMS	Enrollment, days 1, 3, 5, and 7.	Discontinue: PCT <0.25 ng/mL	PCT=826 SOC=830	AB duration: 4.2 vs 4.3 days, $p = .87$. Adverse outcomes 11.7% vs. 13.1%, $p ≤ .001$
Masia, 2017, Spain[102]	Adults in ED with suspected pneumonia, single center	BRAHMS PCT-Q	Not reported	Discontinue: PCT <0.5 ng/mL: Azythromycin PCT >0.5 ng/mL: levofloxacin	Azythromycin group=216 Levofloxacin group=37	Clinical cure rate: 95.8% (Azithromycine group) vs 94.6% (levofloxacin group)
Corti, 2016, Denmark[90]	Adults admitted with COPD, single center	Mini Vidas	Within 24h of admission, and on days 3, 5 and 7.	Discontinue: PCT <0.25 ng/mL or ≥ 80% drop from peak value	PCT=62 SOC=58	AB duration: 3.5 vs. 8.5 days, $p = 0.02$. 30-day mortality: 3% vs. 2%, $p = 1.000$
Branche, 2015, USA[100]	Adults with LRTI, single center	VIDAS BRAHMS	On enrollment and at 12-24 h.	Discontinue: PCT < 0.25 ng/mL	PCT=151 SOC=149	AB duration: 3 vs 4 days, $p = 0.71$.
Verduri, 2015, Italy[91]	Adults with COPD, multicenter	Kryptor PCT; Brahms	On admission, day 1 and 2	Discontinue: PCT <0.25 ng/mL	PCT=88 SOC=90	Patients with at least 1 exacerbation: 31.8 vs 27.8%, (90% CI: 4.04 (−7.23;15.31))

(Continued)

Table 2. (Continued)

AUTHOR, YEAR, COUNTRY [REF]	SETTING	ASSAY USED	FREQUENCY OF PCT MEASUREMENT	PCT ALGORITHM	SAMPLE SIZE	OUTCOMES: PCT VS SOC
Baer, 2013, Switzerland[87]	Children and adolescents in ED with LRTI, multicenter	B.R.A.H.M.S. PCT sensitive Kryptor®	On enrollment and day 3 and 5.	Discontinue: PCT <0.25ng/mL	PCT=168 SOC=169	AB duration:4.5 vs 6.3 days, $p=P=0.039$
Esposito, 2011, Italy[88]	Children aged >1 month and <14years with CAP, single center	Kryptor PCT, Brahms	On enrollment and every 2days until discharge	Discontinue: PCT <0.25ng/mL	PCT=155 SOC=155	Adverse events: 3.9 vs 25.2%, $p<.05$
Long, 2011, China[94]	Adults with CAP, multicenter	BRAHMS Kryptor	At admission and days 3, 6, and 8.	PCT <0.25ng/mL	PCT=81 SOC=81	AB duration: 5 vs 7days, $p<.001$
Burkhardt, 2010, Germany[104]	Adults with LRTI, multicenter	BRAHMS Kryptor	Not reported	Discontinue: PCT < 0.25ng/mL	PCT=275 SOC=275	AB duration: 7.7 vs 8.6days, $p=.68$
Kristoffersen, 2009, Denmark[106]	Adults with suspicion of pneumonia, multicenter	BRAHMS Kryptor	On admission	Discontinue: PCT <0.25ng/mL	PCT=103 SOC=107	AB duration: 5.1 vs 6.8days, $p=.007$
Schuetz, 2009, Switzerland[98]	Adults in ED with LRTI, multicenter	BRAHMS Kryptor	At admission, on days 3, 5, 7 and at hospital discharge.	PCT <0.25 ng/mL or ≥ 80% drop from peak value	PCT=130 SOC=130	AB duration: 5.7 vs 8.7 days (relative change −34.8%, 95% CI −40.3% to −28.7%). 30-day mortality: 5.1% vs 4.8%, risk difference 0.3 (95% CI -2.1 to 2.5).
Stolz, 2009, Switzerland[101]	Adults in ICU with VAP, multicenter	BRAHMS Kryptor	At admission, on day 2, then daily until day 10.	PCT <0.5ng/mL or ≥80% drop from peak value	PCT=51 SOC=50	AB duration: 27% reduction in PCT group, $p=.038$. 28-days mortality: 16% vs. 24%, $p=0.327$.
Briel, 2008, Switzerland[99]	Adults with LRTI, multicenter	BRAHMS Kryptor	At admission, and on day 3.	Discontinue: PCT <0.25ng/mL	PCT=231 SOC=224	AB duration: 6.2 vs 7.1days, adjusted decrease with PCT 1 day (95% CI 0.4 to 1.7days).
Stolz, 2007, Switzerland[92]	>40years of age COPD patients, single center	BRAHMS Kryptor	At admission, 6-24h if AB is withheld	Discontinue: PCT <0.25ng/mL	PCT=102 SOC=106	AB prescription: 40% vs 72%, $p=.0001$
Christ-Crain, 2006, Switzerland[93]	Adults with CAP, single center	BRAHMS Kryptor	At admission, on days 4, 6 and 8.	Discontinue: PCT <0.25ng/mL	PCT=151 SOC=151	AB duration: 5.8 vs 12.9days, $p<.001$. 30-day mortality: 12% vs 13%, $p=.73$
Christ-Crain, 2004, Switzerland[107]	Adults with LRTI, single center	BRAHMS Kryptor	At admission, 6-24h if AB is withheld	Discontinue: PCT <0.25ng/mL	PCT=124 SOC=119	AB duration: 10.9 vs 12.8days, $p=.03$

AB: antibiotics; CAP: community acquired pneumonia; COPD: chronic obstructive pulmonary disease; ED: emergency department; LRTI: lower respiratory tract infection; ICU: intensive care unit; PCT: procalcitonin; SOC: standard of care.

PCT-guided approaches, considering parameters such as the epidemiology of sepsis cases, hospital *C. difficile* cases, and AMR cases; days on antimicrobial therapy; length of stay due to AMR and *C. difficile* infection; number of PCT tests per patient; and effectiveness in reducing antibiotic therapy days, *C. difficile infection*, and AMR. The finding indicated that implementing a PCT-guided approach could avoid 734.5 thousand antibiotic treatment days [95% CI: 1,105.2;438.8], 7.9 thousand antibiotic-resistant cases [95% CI: 18.5;8.5], and 5.1 thousand *C. difficile* cases [95% CI: 6.7;4.2] per year. This equates to a savings of 83.0 million USD [95% CI: $183.6; $57.7] for the entire health system. A similar economical evaluation by Mewes et al. focusing on US-based studies, also found cost benefits associated with the PCT-guided approach.[111] Specifically, for sepsis patients, the PCT group showed a reduction in antibiotic duration by 5.83 days. Additionally, the length of stay in general wards and ICUs was shortened by 0.7 days and 3.6 days, respectively. The incremental costs for the PCT group were-$11,311 per patient. Furthermore, the study estimated that the incidence of antibiotic-resistant infections was 6.4% lower in the PCT-guided care group compared to standard care (206,442 vs. 193,219 patients).

Conclusion

Evidence from randomized controlled trials (RCTs) and meta-analyses indicates that procalcitonin (PCT)-guided antibiotic stewardship is particularly effective for discontinuing antibiotic therapy. This approach helps reduce the duration of antibiotic exposure, shorten hospital stay, and achieve significant cost saving. However, using PCT guidance to initiate antibiotics has not demonstrated notable clinical or economic benefits compared to standard care (SOC), while the decision to implement PCT-guided antibiotic stewardship should be tailored to individual clinical settings, applying this approach for antibiotic discontinuation in sepsis and patients with lower respiratory tract infections (LRTI) could be advantageous.

List of Abbreviations

AB	Antibiotic
AMR	Antimicrobial Resistance
CAP	community acquired pneumonia
CKD	chronic kidney disease
COPD	Chronic Obstructive Pulmonary Disease
CRP	C-reactive protein
CT	Calcitonin
CT-mRNA	Calcitonin messenger RNA
ED	emergency department
EDTA	Ethylene diamine tetra-acetic acid
ELISA	Enzyme linked immunosorbent assay
EOS	Early onset sepsis
GA	Gestational age
ICU	Intensive care unit
IFN-γ	Interferon gamma
IL-1	Interleukin-1
IL-6	Interleukin -6
IQR	Interquartile range
LOS	Late onset sepsis
LPS	lipopolysaccharide
LRTI	Lower respiratory tract infection
MW	Molecular weight
PASS	Procalcitonin and Survival Study
PCT	Procalcitonin
POC	Point of care
RCTs	Randomized controlled trials
RNA	Ribonucleic acid
SIRS	Systemic inflammatory response syndrome
SOC	Standard of care
TNF-α	Tumor necrosis alpha
VAP	Ventilator associated pneumonia
WBCs	white blood cells

Declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Author Contributions

Conceptualization G.T.K.; methodology, G.T.K., E.T.A, G.A. and Z.M.; validation, G.T.K., E.T.A, G.A. and Z.M.; investigation, G.T.K., E.T.A, G.A. and Z.M.; data curation, G.T.K.; writing—original draft preparation, G.T.K.; writing—review and editing, G.T.K., E.T.A, G.A. and Z.M.; visualization, G.T.K., E.T.A, G.A. and Z.M.; supervision, G.A. and Z.M. All authors have read and agreed to the published version of the manuscript.

Competing interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Availability of data and materials

All data are available in the document

Supplemental material

Supplemental material for this article is available online.

REFERENCES

1. Li Y, Guo J, Yang H, et al. Comparison of culture-negative and culture-positive sepsis or septic shock: a systematic review and meta-analysis. *Crit Care*. 2021 Dec 1;25(1).
2. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. *Crit Care Med*. 2021;49(11):p e1063-e1143.
3. Neyton LPA, Langelier CR, Calfee CS. Metagenomic sequencing in the ICU for precision diagnosis of critical infectious illnesses. *Crit Care*. 2023;27(1):1–7.
4. Baur D, Gladstone BP, Burkert F, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. *Lancet Infect Dis*. 2017;17(9):990–1001.
5. Sadatsharifi A, Davarpanah M-A, Namazi S, et al. *Economic burden of inappropriate empiric antibiotic therapy: a report from Southern Iran*. 2019.
6. Pierrakos C, Velissaris D, Bisdorff M, et al. Biomarkers of sepsis: time for a reappraisal. *Crit Care*. 2020;24:287.
7. Póvoa P, Coelho L, Dal-Pizzol F, et al. How to use biomarkers of infection or sepsis at the bedside: guide to clinicians. *Intensive Care Med*. 2023;49(2):142–53.
8. Kim MH. An update on sepsis biomarkers. *Infect Chemother*. 2020;52(1):1–18.
9. Downes KJ, Fitzgerald JC WS. Utility of procalcitonin as a biomarker for sepsis in children. *J Clin Microbiol*. 2020;58(7):e01851-e01859.
10. Kyriazopoulou EG-BE. Antimicrobial stewardship using biomarkers: accumulating evidence for the critically ill. *Antibiotics*. 2022;11(3):367.
11. Annane D, Maxime V, Faller JP, et al. Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: A randomised controlled trial. *BMJ Open*. 2013;3:e002186.
12. Bloos F, Trips E, Nierhaus A, et al. Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: A randomized clinical trial. *JAMA Intern Med*. 2016;176:1266–1276.
13. Jeon K, Suh JK, Jang EJ, et al. Procalcitonin-guided treatment on duration of antibiotic therapy and cost in septic patients (PRODA): a multi-center randomized controlled trial. *J Korean Med Sci*. 2019;34:e110.
14. Ming J. Procalcitonin: uses in the clinical laboratory for the diagnosis of sepsis. *Lab Med*. 2010;41(3):173–7.
15. Chambliss AB, Patel K, Colón-Franco JM, et al. AACC guidance document on the clinical use of procalcitonin. *J Appl Lab Med*. 2023;8(3):598–634.
16. Beat M, Jon CW, Eric SN, et al. Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis. *J Clin Endocrinol Metab*. 2001;86(1):396–404.
17. Maruna P, Nedelnikova K. Physiology and genetics of procalcitonin. *Physiol Res*. 2000;49(1):57–61.
18. Vijayan AL, Ravindran S, Saikant R, et al. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. *J Intensive Care*. 2017;5(1):45.
19. Lippi G, Sanchis-Gomar F. Procalcitonin in inflammatory bowel disease: drawbacks and opportunities. *World J Gastroenterol*. 2017;23(47):8283–90.
20. Morgenthaler NG, Struck J, Chancerelle Y, et al. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection. *Horm Metab Res*. 2003;35:290–5.
21. Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. *Lancet*. 1993;341:515–8.
22. Samsudin I, Vasikaran SD. Clinical utility and measurement of procalcitonin. *Clin Biochem Rev*. 2017;38(2):59.
23. Nijsten MWN, Olinga P, Hauw The T, et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. *Crit Care Med*. 2000;28(2):458–61.
24. Liu D, Su L, Han G, et al. Prognostic value of procalcitonin in adult patients with sepsis: a systematic review and meta-analysis. *PLoS One*. 2015;10(6):129450.
25. Peng JC, Xu QY, Ding J, et al. Usefulness of procalcitonin clearance to predict mortality in abdominal sepsis. *Eur J Inflamm*. 2020;18:125.
26. Schuetz P, Birkhahn R, Sherwin R, et al. Serial procalcitonin predicts mortality in severe sepsis patients: results from the multicenter procalcitonin monitoring sepsis (MOSES) study. *Crit Care Med*. 2017;45(5):781–9.
27. Shi Y, Peng JM, Hu XY, et al. The utility of initial procalcitonin and procalcitonin clearance for prediction of bacterial infection and outcome in critically ill patients with autoimmune diseases: a prospective observational study. *BMC Anesthesiol*. 2015;15(1):5.
28. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. *Crit Care Med*. 2008;36(3):941–52.
29. Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. *BMC Med*. 2011;9:107.
30. Wu SC, Liang CX, Zhang YL, et al. Elevated serum procalcitonin level in patients with chronic kidney disease without infection: a case-control study. *J Clin Lab Anal*. 2020;34(2):45.
31. Chun K, Chung W, Kim AJ, et al. Association between acute kidney injury and serum procalcitonin levels and their diagnostic usefulness in critically ill patients. *Sci Reports*. 2019;9(1):1–8.
32. Bansal V, Fareed D, Hoppensteadt D, et al. Increased procalcitonin levels in end stage renal disease and chronic kidney disease as an indicator of inflammatory activation. *Blood*. 2008;112(11):5472–5472.
33. El-sayed D, Grotts J, Golgert WA, et al. Sensitivity and specificity of procalcitonin in predicting bacterial infections in patients with renal impairment. *Open Forum Infect Dis*. 2014;1(2):15.
34. Dahaba AA, Rehak PH, List WF. Procalcitonin and C-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis. *Intensive Care Med*. 2003;29(4):579–83.
35. Meisner M, Schmidt J, Hüttner H, et al. The natural elimination rate of procalcitonin in patients with normal and impaired renal function. *Intensive Care Med*. 2000;26(2):S212–S216.
36. Meisner M, Lohs T, Huettemann E, et al. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. *Eur J Anaesthesiol*. 2001;18(2):79–87.
37. Svaldi M, Hirber J, Lanthaler AI, et al. Procalcitonin-reduced sensitivity and specificity in heavily leucopenic and immunosuppressed patients. *Br J Haematol*. 2001;115(1):53–7.
38. Mikuła T, Cianciara J, Wiercińska-Drapało A. Is there any influence of immune deficit on procalcitonin results? *Hum Immunol*. 2011;72(12):1194–7.
39. Smith SE, Muir J, Kalabalik-Hoganson J. Procalcitonin in special patient populations: guidance for antimicrobial therapy. *Am J Heal Pharm*. 2020;77(10):745–58.
40. Chae H, Bevins N, Seymann GB, Fitzgerald RL. Diagnostic value of procalcitonin in transplant patients receiving immunosuppressant drugs: a retrospective electronic medical record–based analysis. *Am J Clin Pathol*. 2021;156(6):1083–1091.
41. Wu CW, Wu JY, Chen CK, et al. Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis. *Support Care Cancer*. 2015;23(10):2863–72.
42. Bele N, Darmon M, Coquet I, et al. Diagnostic accuracy of procalcitonin in critically ill immunocompromised patients. *BMC Infect Dis*. 2011;11:224.
43. Yu XY, Wang Y, Zhong H, et al. Diagnostic value of serum procalcitonin in solid organ transplant recipients: a systematic review and meta-analysis. *Transplant Proc*. 2014;46(1):26-32.
44. Lapillonne A, Basson N, Monneret G, et al. Lack of specificity of procalcitonin for sepsis diagnosis in premature infants. *Lancet*. 1998;351(9110):1211-1212.
45. Rossum AMCV, Wulkan RW, Oudesluys-Murphy AM. Procalcitonin as an early marker of infection in neonates and children. *Lancet Infect Dis*. 2004;4(10):620-630.
46. Turner D, Hammerman C, Rudensky B, et al. Procalcitonin in preterm infants during the first few days of life: introducing an age related nomogram. *Arch Dis Child Fetal Neonatal Ed*. 2006;91(4):5.
47. Altunhan H, Annagür A, Örs R, et al. Procalcitonin measurement at 24 hours of age may be helpful in the prompt diagnosis of early-onset neonatal sepsis. *Int J Infect Dis*. 2011;15(12):e854–8.
48. Chiesa C, Panero A, Rossi N, et al. Reliability of procalcitonin concentrations for the diagnosis of sepsis in critically ill neonates. *Clin Infect Dis*. 1998;26(3):664–72.
49. Boscarino G, Migliorino R, Carbone G, Davino G, et al. Biomarkers of neonatal sepsis: where we are and where we are going. *Antibiotics*. 202;12(8):54.
50. Stocker M, Hop WCJ, van Rossum AMC. Neonatal Procalcitonin Intervention Study (NeoPInS): Effect of Procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early-onset sepsis: a multi-centre randomized superiority and non-inferiority intervention study. *BMC Pediatr*. 2010;10:89.
51. Schneider HG, Lam QT. Procalcitonin for the clinical laboratory: a review. *Pathology*. 2007;39(4):383–390.
52. Quan L, Hong Z, Xiaoyan D, et al. Consistency of peripheral whole blood and venous serum procalcitonin in children: a multicenter parallel controlled study. *Zhonghua er ke za zhi = Chinese J Pediatr*. 2021;59(6):471-477.
53. Sheng H, Zhang X, Peng Z, et al. The effects of different blood sample types on quantitative detection of procalcitonin. *Clin Lab*. 2022;68(2):359–65.
54. Chiravuri S. *Pancytopenia*. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK563146/
55. Schuetz P, Bretscher C, Bernasconi L, et al. Overview of procalcitonin assays and procalcitonin-guided protocols for the management of patients with infections and sepsis. *Expert Rev Mol Diagn*. 2017;17(6):593–601.

56. Thermo Scientific BRAHMSPCTLIA. 2012. www.thermoscientific.com/kryptor

57. Fortunato A. *A new sensitive automated assay for procalcitonin detection.* LIAISON® BRAHMS PCT® II GEN. Pract Lab Med. 2016 Dec 12;6:1.

58. Dipalo M, Guido L, Micca G, et al. Multicenter comparison of automated procalcitonin immunoassays. *Pract Lab Med*. 2015;2:22.

59. Ito A, Ishida T. Diagnostic markers for community-acquired pneumonia. *Ann Transl Med*. 2020;8(9):609–609.

60. Ciriello V, Gudipati S, Stavrou PZ, et al. Biomarkers predicting sepsis in polytrauma patients: current evidence. *Injury*. 2013;44(12):1680–92.

61. Sakran JV, Michetti CP, Sheridan MJ, et al. The utility of procalcitonin in critically ill trauma patients. *J Trauma Acute Care Surg*. 2012;73(2):413–8.

62. Cabral L, Afreixo V, Meireles R, et al. Procalcitonin kinetics after burn injury and burn surgery in septic and non-septic patients—A retrospective observational study. *BMC Anesthesiol*. 2018;18(1):1–10.

63. Lavrentieva A, Papadopoulou S, Kioumis J, et al. PCT as a diagnostic and prognostic tool in burn patients. Whether time course has a role in monitoring sepsis treatment. *Burns*. 2012;38(3):356–63.

64. Spoto S, Valeriani E, Caputo D, et al. The role of procalcitonin in the diagnosis of bacterial infection after major abdominal surgery: advantage from daily measurement. *Medicine*. 2018;97(3):87.

65. Elyazed MMA, Zaki MES. Value of procalcitonin as a biomarker for postoperative hospital-acquired pneumonia after abdominal surgery. *Korean J Anesthesiol*. 2017;70(2):177.

66. Layios N, Lambermont B, Canivet JL, et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. *Crit Care Med*. 2012;40(8):2304-2319.

67. Jensen JU, Hein L, Lundgren B, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. *Crit Care Med*. 2011;39(9):2048–58.

68. Peng F, Chang W, Xie JF, et al. Ineffectiveness of procalcitonin-guided antibiotic therapy in severely critically ill patients: a meta-analysis. *Int J Infect Dis*. 2019;85:158-166.

69. Huang HB, Peng JM, Weng L, et al. Procalcitonin-guided antibiotic therapy in intensive care unit patients: a systematic review and meta-analysis. *Ann Intensive Care*. 2017;7(1):114.

70. Prkno A, Wacker C, Brunkhorst FM. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock–a systematic review and meta-analysis. *Crit Care*. 2013;17(6):R291.

71. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an Antibiotic stewardship program: guidelines by the infectious diseases society of America and the society for healthcare epidemiology of America. *Clin Infect Dis An Off Publ Infect Dis Soc Am*. 2016;62(10):e51.

72. Ali WA, Bazan NS, Elberry AA, et al. A randomized trial to compare procalcitonin and C-reactive protein in assessing severity of sepsis and in guiding antibacterial therapy in Egyptian critically ill patients. *Ir J Med Sci*. 2021;190(4):1487–95.

73. Kyriazopoulou E, Liaskou-Antoniou L, Adamis G, et al. Procalcitonin to reduce long-term infection-associated adverse events in sepsis. A randomized trial. *Am J Respir Crit Care Med*. 2021;203(2):202–10.

74. Jeon K, Suh JK, Jang EJ, et al. Procalcitonin-guided treatment on duration of antibiotic therapy and cost in septic patients (PRODA): a multi-center randomized controlled trial. *J Korean Med Sci*. 2019;34(14):e110.

75. Stocker M, van Herk W, El Helou S, et al. Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns). *Lancet*. 2017;390(10097):871–81.

76. Bloos F, Trips E, Nierhaus A, et al. Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. *JAMA Intern Med*. 2016;176(9):1266-1276.

77. de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. *Lancet Infect Dis*. 2016;16(7):819–27.

78. Shehabi Y, Sterba M, Garrett PM, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. *Am J Respir Crit Care Med*. 2014;190(10):1102-1110.

79. Deliberato RO, Marra AR, Sanches PR, et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. *Diagn Microbiol Infect Dis*. 2013;76(3):266-271.

80. Oliveira CF, Botoni FA, Oliveira CRA, Silva CB, Pereira HA, Serufo JC, et al. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. *Crit Care Med*. 2013;41(10):2336–43.

81. Stocker M, Fontana M, El Helou S, et al. Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial. *Neonatology*. 2010;97(2):165–74.

82. Bouadma L, Luyt C-E, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. *Lancet*. 2010;375(9713):463-474.

83. Hochreiter M, Köhler T, Schweiger AM, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. *Crit Care*. 2009;13(3):R83.

84. Schroeder S, Hochreiter M, Koehler T, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. *Langenbeck's Arch Surg*. 2009;394(2):221-226.

85. Nobre V, Harbarth S, Graf J-D, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. *Am J Respir Crit Care Med*. 2008;177(5):498-505.

86. Gavazzi G, Drevet S, Debray M, et al. Procalcitonin to reduce exposure to antibiotics and individualise treatment in hospitalised old patients with pneumonia: a randomised study. *BMC Geriatr*. 2022;22(1):965.

87. Baer G, Baumann P, Buettcher M, et al. Procalcitonin guidance to reduce antibiotic treatment of lower respiratory tract infection in children and adolescents (ProPAED): a randomized controlled trial. *PLoS One*. 2013;8(8):e68419.

88. Esposito S, Tagliabue C, Picciolli I, et al. Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia. *Respir Med*. 2011;105(12):1939-1945.

89. Daubin C, Valette X, Thiollière F, et al. Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study. *Intensive Care Med*. 2018;44(4):428-437.

90. Corti C, Fally M, Fabricius-Bjerre A, et al. Point-of-care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD. *Int J Chron Obstruct Pulmon Dis*. 2016;11:1381–9.

91. Verduri A, Luppi F, D'Amico R, et al. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. *PLoS One*. 2015;10(3):e0118241.

92. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. *Chest*. 2007;131(1):9–19.

93. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. *Am J Respir Crit Care Med*. 2006;174(1):84–93.

94. Long W, Deng X, Zhang Y, et al. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. *Respirology*. 2011;16(5):819–24.

95. Montassier E, Javaudin F, Moustafa F, et al. Guideline-based clinical assessment versus procalcitonin-guided antibiotic use in pneumonia: a pragmatic randomized trial. *Ann Emerg Med*. 2019;74(4):580-591.

96. Z Mazlan M, Ismail M, Ali S, et al. Efficacy and safety of the point-of-care procalcitonin test for determining the antibiotic treatment duration in patients with ventilator-associated pneumonia in the intensive care unit: a randomised controlled trial. *Anaesthesiol Intensive Ther*. 2021;53(3):207-214.

97. Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. *N Engl J Med*. 2018;379(3):236-249.

98. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. *JAMA*. 2009;302(10):1059–66.

99. Briel M, Schuetz P, Mueller B, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. *Arch Intern Med*. 2008;168(18):2000–8.

100. Branche AR, Walsh EE, Vargas R, et al. Serum procalcitonin measurement and viral testing to guide antibiotic use for respiratory infections in hospitalized adults: a randomized controlled trial. *J Infect Dis*. 2015;212(11):1692–700.

101. Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. *Eur Respir J*. 2009;34(6):1364-1375.

102. Masiá M, Padilla S, Ortiz de Tabla V, et al. Procalcitonin for selecting the antibiotic regimen in outpatients with low-risk community-acquired pneumonia using a rapid point-of-care testing: a single-arm clinical trial. *PLoS One*. 2017;12(4):e0175634.

103. Wussler D, Kozhuharov N, Oliveira MT, et al. Clinical utility of procalcitonin in the diagnosis of pneumonia. *Clin Chem*. 2019;65(12):1532–42.

104. Burkhardt O, Ewig S, Haagen U, et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. *Eur Respir J*. 2010;36(3):601-607.

105. Lhopitallier L, Kronenberg A, Meuwly J-Y, et al. Procalcitonin and lung ultrasonography point-of-care testing to determine antibiotic prescription in patients with lower respiratory tract infection in primary care: pragmatic cluster randomised trial. *BMJ*. 2021;374:n2132.

106. Kristoffersen KB, Søgaard OS, Wejse C, et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single

procalcitonin measurement at hospital admission—A randomized trial. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2009;15(5): 481-487.

107. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. *Lancet*. 2004; 363(9409):600-607.

108. Garnfeldt VM, Vincent JL, Gruson D, et al. The budget impact of procalcitonin-guided antibiotic stewardship compared to standard of care for patients with suspected sepsis admitted to the intensive care unit in Belgium. *PLoS One*. 2023;18(10):e0293544.

109. Geraerds A, van Herk W, Stocker M, et al. Cost impact of procalcitonin-guided decision making on duration of antibiotic therapy for suspected early-onset sepsis in neonates. *Crit Care*. 2021;25(1):367.

110. Garay OU, Guiñazú G, Cornistein W, et al. Budget impact analysis of using procalcitonin to optimize antimicrobial treatment for patients with suspected sepsis in the intensive care unit and hospitalized lower respiratory tract infections in Argentina. *PLoS One*. 2021;16(4):56.

111. Mewes JC, Pulia MS, Mansour MK, et al. The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patients with suspected sepsis or lower respiratory tract infections in the US: a health economic model analysis. *PLoS One*. 2019;14(4):e0214222.